Day One Biopharmaceuticals (DAWN) News Today $13.31 -1.01 (-7.05%) (As of 11/15/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period 59,259 Shares in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Bought by GSA Capital Partners LLPGSA Capital Partners LLP bought a new stake in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 59,259 shares of the company's stock, valued at approximNovember 17 at 3:52 AM | marketbeat.comDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Insider Samuel C. Blackman Sells 10,000 SharesNovember 13, 2024 | insidertrades.comDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Shares Purchased by TimesSquare Capital Management LLCTimesSquare Capital Management LLC grew its stake in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) by 8.2% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,827,695 shares of the company's sNovember 11, 2024 | marketbeat.comSamuel C. Blackman Sells 11,245 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) StockNovember 9, 2024 | insidertrades.comDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Insider Sells $180,257.35 in StockDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Get Free Report) insider Samuel C. Blackman sold 11,245 shares of Day One Biopharmaceuticals stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $16.03, for a total value of $180,257.35. Following the completion of the sale, the insider now directly owns 1,085,790 shares in the company, valued at $17,405,213.70. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.November 8, 2024 | marketbeat.comDay One Biopharmaceuticals (NASDAQ:DAWN) Stock Rating Upgraded by TD CowenTD Cowen raised Day One Biopharmaceuticals to a "strong-buy" rating in a research report on Monday.November 5, 2024 | marketbeat.comBullish: Analysts Just Made A Huge Upgrade To Their Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) ForecastsNovember 4, 2024 | finance.yahoo.comDay One Biopharmaceuticals: Strong Ojemda Launch Exceeds Expectations, Analyst Reiterates Overweight RatingNovember 4, 2024 | markets.businessinsider.comWhat is HC Wainwright's Estimate for DAWN Q1 Earnings?Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) - Equities research analysts at HC Wainwright issued their Q1 2025 EPS estimates for shares of Day One Biopharmaceuticals in a note issued to investors on Thursday, October 31st. HC Wainwright analyst A. Maldonado forecasts that the comNovember 4, 2024 | marketbeat.comDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Receives Consensus Rating of "Moderate Buy" from BrokeragesShares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Get Free Report) have earned a consensus rating of "Moderate Buy" from the eight brokerages that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a hold rating and seven have asNovember 3, 2024 | marketbeat.comWe Think Day One Biopharmaceuticals (NASDAQ:DAWN) Can Easily Afford To Drive Business GrowthNovember 2, 2024 | finance.yahoo.comDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Q3 2024 Earnings Call TranscriptNovember 2, 2024 | insidermonkey.comDay One Biopharmaceuticals, Inc.: Day One Reports Third Quarter 2024 Financial Results and Corporate ProgressNovember 1, 2024 | finanznachrichten.deBuy Rating Affirmed for Day One Biopharmaceuticals Amid Strong Ojemda Launch and Strategic Ipsen PartnershipOctober 31, 2024 | markets.businessinsider.comBuy Rating Affirmed for Day One Biopharmaceuticals Amid Strong Ojemda Sales and Strategic Growth ProspectsOctober 31, 2024 | markets.businessinsider.comPiper Sandler Sticks to Its Buy Rating for Day One Biopharmaceuticals (DAWN)October 31, 2024 | markets.businessinsider.comDay One Biopharmaceuticals (NASDAQ:DAWN) Releases Earnings Results, Beats Estimates By $0.58 EPSDay One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) announced its quarterly earnings data on Wednesday. The company reported $0.38 earnings per share for the quarter, topping the consensus estimate of ($0.20) by $0.58. The firm had revenue of $93.76 million for the quarter, compared to analyst estimates of $15.05 million. During the same period in the previous year, the business posted ($0.54) EPS.October 31, 2024 | marketbeat.comDay One Biopharmaceuticals (NASDAQ:DAWN) Shares Gap Up After Earnings BeatDay One Biopharmaceuticals (NASDAQ:DAWN) Shares Gap Up on Strong EarningsOctober 31, 2024 | marketbeat.comDay One Biopharmaceuticals (NASDAQ:DAWN) Receives Buy Rating from HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $40.00 price objective on shares of Day One Biopharmaceuticals in a research report on Thursday.October 31, 2024 | marketbeat.comStrong Buy Recommendation for Day One Biopharmaceuticals Driven by Impressive Revenue Growth and Strategic Market ExpansionOctober 31, 2024 | markets.businessinsider.comBuy Rating Affirmed for Day One Biopharmaceuticals on Strong Ojemda Performance and Pipeline Expansion ProspectsOctober 31, 2024 | markets.businessinsider.comDay One Biopharmaceuticals Reports Strong Q3 with OJEMDAOctober 31, 2024 | markets.businessinsider.comDay One Reports Third Quarter 2024 Financial Results and Corporate ProgressOctober 30, 2024 | globenewswire.comDay One Biopharmaceuticals (NASDAQ:DAWN) Shares Gap Up - Here's WhyDay One Biopharmaceuticals (NASDAQ:DAWN) Shares Gap Up - Here's What HappenedOctober 23, 2024 | marketbeat.comDay One Biopharmaceuticals (DAWN) Scheduled to Post Earnings on WednesdayDay One Biopharmaceuticals (NASDAQ:DAWN) will be releasing earnings after the market closes on Wednesday, October 30, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=588222)October 23, 2024 | marketbeat.comDAWN Q3 EPS Estimate Boosted by Capital One FinancialDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) - Analysts at Capital One Financial upped their Q3 2024 EPS estimates for Day One Biopharmaceuticals in a research note issued on Wednesday, October 16th. Capital One Financial analyst N. Quibria now expects that the company will post eOctober 21, 2024 | marketbeat.comDay One Biopharmaceuticals (DAWN): Advancing Targeted Therapies for Pediatric GliomaOctober 17, 2024 | msn.comDay One to Report Third Quarter 2024 Financial Results Wednesday, October 30, 2024October 16, 2024 | globenewswire.com184,230 Shares in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Purchased by Essex Investment Management Co. LLCEssex Investment Management Co. LLC bought a new stake in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund bought 184,230 shares of the company's stock, valued at approximatelOctober 13, 2024 | marketbeat.comAQR Capital Management LLC Buys 94,703 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)AQR Capital Management LLC raised its stake in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) by 517.0% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 113,020 shares of the company's stock after purchOctober 11, 2024 | marketbeat.comDay One Biopharmaceuticals (NASDAQ:DAWN) Shares Up 5.2% Following Analyst UpgradeDay One Biopharmaceuticals (NASDAQ:DAWN) Shares Up 5.2% After Analyst UpgradeOctober 9, 2024 | marketbeat.comRenaissance Technologies LLC Acquires New Stake in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)Renaissance Technologies LLC bought a new position in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) in the second quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 72,140 shares of the company's stock, valued at appOctober 7, 2024 | marketbeat.comDay One Biopharmaceutical (NASDAQ:DAWN) Stock Quotes, Forecast and News SummaryOctober 5, 2024 | benzinga.comDay One Biopharmaceuticals (NASDAQ:DAWN) Stock Price Up 4.2%Day One Biopharmaceuticals (NASDAQ:DAWN) Stock Price Up 4.2%October 3, 2024 | marketbeat.comSquarepoint Ops LLC Makes New $2.57 Million Investment in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)Squarepoint Ops LLC purchased a new position in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 186,484 shares of the company's stock, valued atOctober 3, 2024 | marketbeat.com470,247 Shares in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Bought by Point72 Asset Management L.P.Point72 Asset Management L.P. bought a new stake in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 470,247 shares of the company's stock, valued at apOctober 2, 2024 | marketbeat.comDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Shares Sold by Maverick Capital Ltd.Maverick Capital Ltd. lowered its holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) by 3.6% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,211,138 shares of the company's stock after selliSeptember 27, 2024 | marketbeat.comDeerfield Management Company L.P. Series C Boosts Stock Holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)Deerfield Management Company L.P. Series C grew its position in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) by 65.6% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,923,137 shares of the coSeptember 26, 2024 | marketbeat.comDAWN Jan 2025 12.500 callSeptember 25, 2024 | ca.finance.yahoo.comDay One Biopharmaceuticals (NASDAQ:DAWN) Shares Down 4.8% Day One Biopharmaceuticals (NASDAQ:DAWN) Shares Down 4.8%September 23, 2024 | marketbeat.comAlly Bridge Group NY LLC Makes New $7.39 Million Investment in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)Ally Bridge Group NY LLC acquired a new stake in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) in the second quarter, according to its most recent disclosure with the SEC. The firm acquired 536,095 shares of the company's stock, valued at approximately $7,387,000. Day One BSeptember 23, 2024 | marketbeat.com$24M biotech center at PCTI in Wayne marks 'dawn of a new era' in educationSeptember 20, 2024 | msn.comPolaris Dawn crew members conduct space health experiments for Houston instituteSeptember 15, 2024 | msn.comDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Receives Consensus Recommendation of "Moderate Buy" from AnalystsShares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Get Free Report) have been given an average rating of "Moderate Buy" by the eight ratings firms that are covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and seven have isSeptember 14, 2024 | marketbeat.comDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Insider Sells $426,600.00 in StockSeptember 13, 2024 | insidertrades.comInsider Selling: Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Insider Sells 30,000 Shares of StockDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Get Free Report) insider Samuel C. Blackman sold 30,000 shares of the company's stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $14.22, for a total value of $426,600.00. Following the completion of the sale, the insider now owns 1,097,535 shares in the company, valued at approximately $15,606,947.70. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.September 12, 2024 | marketbeat.comTD Cowen Keeps Their Buy Rating on Day One Biopharmaceuticals (DAWN)September 9, 2024 | markets.businessinsider.comDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Short Interest UpdateDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Get Free Report) was the recipient of a large increase in short interest in the month of August. As of August 15th, there was short interest totalling 13,570,000 shares, an increase of 11.1% from the July 31st total of 12,210,000 shares. Based on an average daily volume of 1,000,000 shares, the short-interest ratio is presently 13.6 days. Currently, 22.9% of the shares of the company are sold short.September 1, 2024 | marketbeat.comInsider Selling: Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Insider Sells 2,232 Shares of StockAugust 20, 2024 | insidertrades.comDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Insider Samuel C. Blackman Sells 2,232 SharesDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Get Free Report) insider Samuel C. Blackman sold 2,232 shares of the company's stock in a transaction on Friday, August 16th. The stock was sold at an average price of $14.00, for a total transaction of $31,248.00. Following the completion of the transaction, the insider now directly owns 1,127,535 shares in the company, valued at $15,785,490. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.August 19, 2024 | marketbeat.com Get Day One Biopharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for DAWN and its competitors with MarketBeat's FREE daily newsletter. Email Address “Fed Proof” Your Bank Account with THESE 4 Simple Steps (Ad)Starting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account. Learn these 4 simple steps and protect your savings before it’s too late. DAWN Media Mentions By Week DAWN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. DAWN News Sentiment▼0.610.56▲Average Medical News Sentiment DAWN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. DAWN Articles This Week▼53▲DAWN Articles Average Week Get Day One Biopharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for DAWN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies MannKind News Today Arcutis Biotherapeutics News Today Castle Biosciences News Today LeMaitre Vascular News Today Sangamo Therapeutics News Today Atai Life Sciences News Today Black Diamond Therapeutics News Today Burning Rock Biotech News Today Blueprint Medicines News Today Lantheus News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:DAWN) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Day One Biopharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Day One Biopharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
